Covalon Technologies Ltd. to Participate in the 2024 Association for Vascular Access Annual Scientific Meeting
September 27 2024 - 6:00AM
Business Wire
Visit Covalon at booth 523 to discover the
latest in compassionate vascular access solutions
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV; OTCQX: CVALF), is pleased to announce its participation in the
2024 Association for Vascular Access (“AVA”) Annual Scientific
Meeting. The event will take place from September 28 to 30 in
Colorado. Founded in 1985, AVA’s multidisciplinary membership is
dedicated to advancing research, providing education, and fostering
collaboration to improve patient outcomes in vascular access.
Covalon is proud to be a part of this esteemed community and to
contribute to the development of evidence-based innovations.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240927012827/en/
(Photo: Business Wire)
“Our participation in the AVA Annual Scientific Meeting
highlights Covalon’s commitment to enhancing patient comfort and
supporting improved vascular access clinical care,” said Brent
Ashton, Chief Executive Officer, Covalon. “Our silicone-adhesive
dressings help to reduce the challenges of cumbersome acrylic
dressing removals, while our vascular access line guard helps to
protect against gross contamination. Together, these products
combine safety, compassion, and innovation to help improve clinical
outcomes."
At booth #523, Covalon will be showcasing its comprehensive
range of compassionate vascular access solutions, including a new
range of CovaClear® IV Vascular Access Dressings. Attendees are
invited to learn more about how these innovative products are
helping healthcare providers deliver exceptional care to patients
around the world. Covalon representatives will be available to
discuss the latest advancements in vascular access technology and
answer any questions.
Covalon’s patented vascular access products include:
- VALGuard® - a transparent line guard designed to protect IV
line connections and hubs from external contaminants, including
body fluids and other secretions.
- SurgiClear® - a dual antimicrobial clear silicone adhesive
dressing with Chlorhexidine and Silver used to cover and protect
wound sites and wound closure devices.
- IV Clear® - a dual antimicrobial (Chlorhexidine and Silver)
clear IV securement dressing that provides antimicrobial protection
throughout the entire dressing surface area.
- CovaClear® IV - a soft silicone adhesive clear IV dressing that
helps protect insertion sites from external contaminants. Suitable
for patients who either don’t require, or cannot tolerate,
antimicrobials.
Scheduling Appointments and Additional Information
To book an appointment with a Covalon representative, please
email Ron Hebert, SVP Growth, Covalon Technologies Ltd., at
rhebert@covalon.com.
Conference Details
- Dates: September 28 – 30 2024
- Location: Gaylord Rockies Resort & Convention Center, 6700
N Gaylord Rockies Blvd, Aurora, CO 80019, United States
- Registration: https://avasm24.eventscribe.net
For healthcare providers unable to attend the conference,
Covalon encourages you to visit www.covalon.com or follow the
company on LinkedIn, Facebook, or Instagram to learn more about its
solutions.
About Covalon
Covalon is a patient-driven medical device company, that
provides innovative and cost-effective healthcare solutions for
advanced wound care, infection control, and medical device
coatings. Through a strong portfolio of patented technologies and
solutions, we offer innovative, gentle and more compassionate
options to aid patients on their healing journey. Our solutions are
designed for patients and made for care providers. Covalon
leverages its patented medical technology platforms and expertise
in two ways: (i) by developing products that are sold under
Covalon’s name; and (ii) by developing and commercializing medical
products for other medical companies under development and license
contracts. The Company is listed on the TSX Venture Exchange,
having the symbol COV and trades on the OTCQX Market under the
symbol CVALF. To learn more about Covalon, visit our website at
www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur”, or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management’s expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the “Risks
and Uncertainties” section of our management’s discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2023, which is available on the Company’s
profile at www.sedarplus.ca, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240927012827/en/
To learn more about Covalon, please contact: Investor Relations,
Covalon Technologies Ltd. Email: investors@covalon.com Website:
https://covalon.com/
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Dec 2023 to Dec 2024